Biopsy Guidance Systems Market | USD 2.83 Billion by 2034
The biopsy guidance systems market size was exhibited at USD 1.55 billion in 2024 and is projected to hit around USD 2.83 billion by 2034, growing at a CAGR of 6.2% during the forecast period 2025 to 2034.
The U.S. biopsy guidance systems market size was valued at USD 0.50 million in 2024 and is expected to reach around USD 1.0 million by 2034, growing at a CAGR of 6.5% from 2025 to 2034.
North America led the biopsy guidance system market in 2024, accounting for a 46.0% revenue share. This dominance is attributed to the continuous expansion and development of companies specializing in cancer diagnostics, increasing demand for innovative solutions, and a rising number of cancer cases. Significant investments in research and development from government organizations, non-profit healthcare institutions, pharmaceutical and biotech companies, and research institutes are expected to propel market growth in the coming years.
U.S. Biopsy Guidance System Market Trends
The U.S. biopsy guidance system market is projected to grow at a CAGR of 6.2% from 2025 to 2034. This growth is primarily driven by the continuous rise in cancer cases, the increasing number of facilities and organizations providing cancer treatment, and advancements in biopsy guidance system technology.
Europe Biopsy Guidance System Market Trends
Europe is recognized as a key region in the biopsy guidance system market. The growing preference for specialty care clinics, the rising incidence of newly diagnosed cancer cases each year, the presence of leading cancer treatment organizations, and increasing awareness about the importance of early cancer treatment are expected to fuel market growth in the coming years.
The UK held the largest revenue share in the European market. This is attributed to factors such as the rising prevalence of various cancer types, including blood cancer, advancements in healthcare infrastructure, initiatives led by the National Health Service (NHS), and the presence of major industry players in the country.
Asia Pacific Biopsy Guidance System Market Trends
The Asia Pacific region is anticipated to witness the fastest CAGR throughout the forecast period. This growth is driven by the increasing number of cancer diagnoses, improved healthcare infrastructure for cancer care and treatment, and the presence of international organizations fostering medical tourism. According to a recent report from the National Cancer Registry Programme (NCRP), cancer cases in India are expected to rise from 1.39 million in 2020 to 1.57 million by 2025.
China accounted for a significant revenue share in the biopsy guidance system market in 2024. This growth is attributed to technological advancements in magnetic resonance imaging (MRI), ultrasound-guided biopsy, CT imaging, and robotic biopsies, along with government support, favorable reimbursement policies, improved healthcare infrastructure, and public health initiatives focused on cancer screening and early detection.
| Report Coverage | Details |
| Market Size in 2025 | USD 1.65 Billion |
| Market Size by 2034 | USD 2.83 Billion |
| Growth Rate From 2025 to 2034 | CAGR of 6.2% |
| Base Year | 2024 |
| Forecast Period | 2025-2034 |
| Segments Covered | Product, Application, End use, Region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional scope | North America; Europe; Asia Pacific; Latin America; MEA |
| Key Companies Profiled | Becton, Dickinson and Company; Hologic, Inc.; Devicor Medical Products, Inc.; B. Braun Melsungen AG; ARGON MEDICAL; Boston Scientific Corporation; INRAD Inc.; Cook Medical; PLANMED OY |
The stereotactic-guided biopsy led the market in 2024, accounting for a 40.0% share. This technique offers advantages such as minimal invasiveness, quick recovery time, and minimal scarring. One of its key benefits is the ability to evaluate small abnormalities that may not be visible on ultrasound, making it a preferable alternative to conventional surgical biopsies. Additionally, the introduction of automated core biopsy devices has increased the adoption of this method.
The ultrasound-guided biopsy segment is projected to record the highest CAGR over the forecast period. It is widely recognized as the most effective real-time imaging tool for guiding percutaneous biopsies and fine-needle aspirations, particularly for abdominal and pelvic organs. The advantages of ultrasound-guided biopsies include compact size, lower costs, and the absence of ionizing radiation exposure compared to CT-guided biopsies. These benefits have contributed to the growing popularity of ultrasound-guided breast biopsies, ultimately driving market expansion.
The healing centers segment dominated the market in 2024, holding the largest revenue share. This can be attributed to the increasing adoption of biopsy guidance systems in healthcare facilities. Patients are increasingly opting for minimally invasive procedures to reduce complications and side effects associated with traditional surgeries. The rising prevalence of cancer is a major driver of growth in this segment. According to the Leukemia & Lymphoma Society (LLS), one person in the U.S. is diagnosed with leukemia, lymphoma, or myeloma every three minutes.
The specialty clinics segment is expected to experience the fastest CAGR during the forecast period. The growing acceptance of single-specialty healthcare facilities has created opportunities for both new and established businesses. Increasing awareness regarding the accessibility of diagnostic and screening procedures for chronic illnesses in specialty clinics has driven demand for stereotactic-guided biopsies. Additionally, these clinics provide tailored, specialized care for various cancer types, supported by dedicated infrastructure, further fueling segment growth.
The brain biopsy segment held the largest market revenue share in 2024. Brain biopsy is considered the most reliable technique for diagnosing brain tumors that cannot be surgically removed. According to an NCBI report from 2024, brain biopsy procedures are associated with low mortality rates and minimal complications. Furthermore, the increasing geriatric population has contributed to the rising number of brain biopsies worldwide. Technological advancements, such as MRI-guided robotic systems for brain biopsies, are expected to further drive market growth.
The breast biopsy segment is anticipated to record the highest CAGR over the forecast period. The increasing incidence of breast cancer is the primary factor driving this segment. Additionally, conditions such as menopause-related health issues and hormonal imbalances are leading to a growing number of breast cancer cases, further boosting demand for breast biopsies.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc. has segmented the biopsy guidance systems market
By Product
By Application
By End Use
By Regional
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers